Different CDK inhibitors target various CDKs. For instance, CDK4/6 inhibitors are among the most commonly used in cancer therapy. These inhibitors specifically target CDK4 and CDK6, which are involved in the transition from the G1 phase to the S phase of the cell cycle. Other CDKs, such as CDK1, CDK2, and CDK9, are also targeted by different inhibitors, albeit less frequently.
